HealthWatch has received a donation of £50,000 from a private individual who supports our aims and objectives, and who has no connection with any pharmaceutical company, nor any financial interest in any complementary or other therapy or treatment, to establish a research fund.
Applications are now invited for funding to support research projects that meet the aims and objectives of HealthWatch.
Applications may be for up to £10,000, but it is anticipated that most will be for lesser amounts.
There is no closing date for applications, which may be made at any time.
Click here for the aims and scope of the HealthWatch Research Fund, and rules governing the application process.
Click here for the application form for funding from the HealthWatch Research Fund.
HealthWatch has from its outset campaigned for clinical trial integrity. For almost a decade we have been raising awareness of concerns over the questionable ethics of the largest randomised controlled trial in history. Known as "AgeX" it was launched in 2010 and at its height aimed to enrol six million women in England to measure effects of extending the age range for routine breast cancer screening from 50-70, to 47-79.
This page details our investigations and exposés.
Related external publications
- Critics say wider breast screening trial 'unethical' (Claire Wilson, New Scientist, 10 Nov 2014)
- Times letter sparks media frenzy: HealthWatch experts urge women to think twice before accepting catch-up screening invites (17 May 2018)
- "'Misleading' invitations left patients feeling manipulated" (Ben Rumsby and Deborah Cohen, The Sunday Telegraph, p 10, 27 May 2018)
- "Cost of extending the NHS breast screening age range in England" (Bewley, Blennerhassett and Payne, The BMJ, 10 April 2019; or read full-text version free here.
Introduction to Unfair Trading.